Production (Stage)
Candel Therapeutics, Inc.
CADL
$5.13
-$0.03-0.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 25.13M | 25.23M | 32.17M | 31.80M | 32.76M |
| Gross Profit | -25.13M | -25.23M | -32.17M | -31.80M | -32.76M |
| SG&A Expenses | 14.73M | 14.40M | 14.32M | 13.99M | 14.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.86M | 32.63M | 35.16M | 35.26M | 36.27M |
| Operating Income | -32.86M | -32.63M | -35.16M | -35.26M | -36.27M |
| Income Before Tax | -39.58M | -55.18M | -52.20M | -49.99M | -37.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.58 | -55.18 | -52.20 | -49.99 | -37.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.58M | -55.18M | -52.20M | -49.99M | -37.37M |
| EBIT | -32.86M | -32.63M | -35.16M | -35.26M | -36.27M |
| EBITDA | -31.87M | -31.64M | -34.16M | -34.27M | -35.29M |
| EPS Basic | -1.33 | -1.75 | -1.74 | -1.70 | -1.29 |
| Normalized Basic EPS | -0.82 | -1.08 | -1.08 | -1.05 | -0.80 |
| EPS Diluted | -1.34 | -1.75 | -1.74 | -1.70 | -1.29 |
| Normalized Diluted EPS | -0.82 | -1.08 | -1.08 | -1.05 | -0.80 |
| Average Basic Shares Outstanding | 147.94M | 126.65M | 120.07M | 116.98M | 116.02M |
| Average Diluted Shares Outstanding | 152.22M | 126.65M | 120.07M | 116.98M | 116.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |